Innoviva Specialty Therapeutics commercial momentum continues with $43.3 million generated in U.S. net product sales, representing 45% year-over-year growth
$58.1 million in quarterly revenue from durable royalty
Presentations span ceftobiprole and zoliflodacin, highlighting post-approval evidence generation across antimicrobial-resistant and difficult-to-treat infections
Innoviva Specialty Therapeutics (IST), a subsidiary of
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as
Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ:INVA), announced today that three of the company’s infectious disease therapies, XACDURO® (sulbactam/durlobactam for injection), ZEVTERA®
IST achieved U.S. net product sales of $36.6 million in the second quarter, representing 26% year-over-year growth
Royalties portfolio generated $59.8 million in second quarter revenue
Launch of wholly-owned
Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive
Company seeks pipeline expansion via industry
Agreement expands access to XACDURO® for patients with serious Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) infections across South and Central America, the Caribbean, Russia and CIS countries
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty
Generated $58.6 million in revenue from resilient royalties portfolio
Achieved IST U.S. net product sales of $34.2 million for the first quarter, representing 29% year-over-year growth
Significant value created
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics
FDA approval was based on results from the largest Phase 3 clinical trial ever conducted for a new treatment against Neisseria gonorrhoeae infection in regions with a high prevalence of gonorrhea across five
Phase 3 findings show oral zoliflodacin to be non-inferior to the combination of ceftriaxone and azithromycin for the treatment of uncomplicated urogenital gonorrhea.
Positive study results are a significant
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics
Generated $63.4 million in revenue from durable royalties portfolio
IST achieved U.S. net product sales of $29.9 million, representing 52% year-over-year growth
Strengthened product portfolio with U.S. launch of
d'Esparbes to lead Antheia's financial strategy as the company continues its global expansionand commercialization
MENLO PARK, Calif., Oct. 21, 2025 /PRNewswire/ -- Antheia, the pharmaceutical ingredient
